5‐Nitrobenzo[c][1, 2, 5]selenadiazole as therapeutic agents in the regulation of oxidative stress and inflammation induced by influenza A(H1N1)pdm09 in vitro and in vivo

Abstract

AbstractCurrently, various problems are being faced in the treatment of influenza, so the development of new safe and effective drugs is crucial. Selenadiazole, an important component of selenium heterocyclic compounds, has received wide attention for its biological activity. This study aimed to verify the antiviral activity of 5‐nitrobenzo[c][1,2,5]selenadiazole (SeD‐3) in vivo and in vitro. The cell counting kit‐8 assay and observation of cytopathic effect verified that SeD‐3 could improve the survival of influenza A(H1N1)pdm09‐infected Madin–Darby canine kidney cells. Polymerase chain reaction quantification and neuraminidase assay showed that SeD‐3 could inhibit the proliferation of H1N1 virus. The time of addition assay demonstrated that SeD‐3 may have a direct effect on virus particles and block some stages of H1N1 life cycle after virus adsorption. Cell cycle, JC‐1, Annexin V, and terminal deoxynucleotidyl transferase (TdT) dUTP nick‐end labeling–4′,6‐diamidino‐2‐phenylindole (TUNEL‐DAPI) assays showed that SeD‐3 inhibited H1N1 infection–induced apoptosis. Cytokine detection demonstrated SeD‐3 inhibited the production of proinflammatory factors after infection, including tumor necrosis factor‐α (TNF‐α), TNF‐β, interferon‐γ, interleukin 12 (IL‐12), and IL‐17F. In vivo experiments suggested that the pathological damage in the lungs was significantly alleviated after treatment with SeD‐3 by hematoxylin and eosin staining. The TUNEL assay of lung tissues indicated that SeD‐3 inhibited DNA damage during H1N1 infection. Immunohistochemical assays were performed to further explore the mechanism that SeD‐3 inhibited H1N1‐induced apoptosis via reactive oxygen species‐mediated MAPK, AKT, and P53 signaling pathways. In conclusion, SeD‐3 may become a new potential anti‐H1N1 influenza virus drug due to its antiviral and anti‐inflammatory activity.